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Background: Biological agents (also termed biologics or biologicals) play a growingly
central role in the treatment of immunological diseases. However, the numerous studies
published on biologics complicate the decision on the most appropriate biologic for a
given disease. We aim to address this problem by publishing a series of systematic
reviews evaluating the safety and efficacy of B cell-targeting biologics for the treatment of
immune-mediated diseases. This article assesses the safety and efficacy of atacicept, a
recombinant fusion protein consisting of the binding portion of transmembrane activator
and CAML interactor (TACI; also known as tumor necrosis factor receptor superfamily
member 13B), which is able to bind the cytokines B cell-activating factor (BAFF) and a
proliferation-inducing ligand (APRIL).
Objective: To evaluate atacicept’s safety and efficacy for the treatment of
immune-mediated disorders compared to placebo, conventional treatment or
other biologics.
Methods: The PRISMA checklist guided the reporting of the data. We searched
the PubMed database between 4 October 2016 and 26 July 2018 concentrating on
immune-mediated disorders.
Results: The literature search identified 118 articles. After screening titles and abstracts
against the inclusion and exclusion criteria and assessing full texts, ten articles were finally
included in a narrative synthesis.
Conclusions: Atacicept failed to show an effect in multiple sclerosis, optic neuritis,
rheumatoid arthritis, and systemic lupus erythematosus. In patients with systemic lupus
erythematosus, atacicept led to increased infection rates, but this adverse effect was not
seen in the other treated diseases.
Keywords: BAFF, APRIL, TACI, B cell, monoclonal antibody, multiple sclerosis, rheumatoid arthritis, systemic
lupus erythematosus
INTRODUCTION
Immune-mediated disorders comprise a heterogeneous group of diseases that are thought to arise
due to dysregulation of immune responses (1). This leads to an imbalance in cytokine networks,
as seen with certain chronic-inflammatory diseases, including psoriasis and inflammatory-bowel
disease, and rare, genetically-caused auto-inflammatory disorders (1, 2). Alternatively, this
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FIGURE 1 | Schematic representation of relevant cytokines and cytokine receptors affected by atacicept. Myeloid cells produce B cell-activating factor (BAFF) and a
proliferation-inducing ligand (APRIL). BAFF is synthesized as a cell membrane-bound protein that can be further processed to soluble BAFF by the action of a
protease. BAFF can interact with the receptors BAFF receptor (BAFF-R), transmembrane activator and CAML interactor (TACI), and B-cell maturation antigen (BCMA),
which are all expressed on B cells and plasma cells. APRIL can only bind to TACI and BCMA. Atacicept is a recombinant fusion protein consisting of the Fc region of
human IgG1 and the binding portion of TACI. Thus, atacicept interferes with the interaction of BAFF and APRIL with their receptors. This in turn results in the inhibition
of mature and immature B cell and plasma cell survival; reduction of serum IgG, IgM, and IgA; and reduction of mature and total circulating B cells.
dysregulation may be caused by a lack of immune tolerance,
which is seen with autoimmune diseases, such as systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), and multiple
sclerosis (MS). Traditional therapies have relied on the use
of corticosteroids and immunosuppressive drugs. However, the
advent of biological agents (also termed biologicals or biologics)
has dramatically changed the standard of care of many immune-
mediated conditions (3). In comparison to corticosteroids and
immunosuppressive drugs, biologics provide the advantage of
targeting a very specific molecule, thereby minimizing off-target
adverse effects.
Since their emergence over 20 years ago, the number of
biologics available has grown rapidly and accordingly the number
of articles published. This makes it difficult for clinicians and
Abbreviations: ACR, American College of Rheumatology; APRIL, a proliferation
inducing ligand; AEs, adverse events; BAFF, B cell activating factor; BCMA,
B cell maturation antigen; BILAG, British Isles Lupus Assessment Group;
BlyS, B-lymphocyte stimulator; CAML, calcium modulating ligand;CAS, clinical
activity score; CRP, C-reactive protein; DAS28, disease activity score 28; ESR,
erythrocyte sedimentation rate; Ig, immunoglobulin; MRI, magnetic resonance
imaging; MS, multiple sclerosis; NSAID, non-steroidal anti-inflammatory drug;
OCT, optical coherence tomography; RA, rheumatoid arthritis; RCT, randomized
controlled trial; RNFL, retinal nerve fiber layer; SAE, serious adverse event; SF-
36, 36-item short form health survey; SLE, systemic lupus erythematosus; TACI,
Transmembrane activator and CAML interactor; TNF, tumor necrosis factor
researchers to have an overview of the safety and efficacy of each
biological agent in order to assess its potential as a treatment
option in immune-mediated diseases (3). In order to facilitate
this task we have designed a series of systematic reviews focusing
on the safety and efficacy of B cell targeting biologics for
the treatment of immune-mediated diseases (4), of which this
systematic review forms part.
Atacicept is a fully human recombinant fusion protein
consisting of the Fc region of human IgG1 and the binding
portion of transmembrane activator and CAML interactor
(TACI; also known as tumor necrosis factor receptor superfamily
member 13B), which is able to bind the cytokines B cell-activating
factor (BAFF; also termed B-lymphocyte stimulator or BlyS) and
a proliferation-inducing ligand (APRIL) (5). Atacicept acts as
a “decoy receptor” for BAFF and APRIL by binding soluble
APRIL, soluble BAFF and membrane-bound BAFF (see below)
(6, 7). Thus, atacicept interferes with the interaction of these
cytokines with their cognate receptors TACI, B-cell maturation
antigen (BCMA; also called TNF receptor superfamily member
17), and BAFF receptor (BAFF-R; also known as TNF receptor
superfamily member 13C) (6). TACI and BCMA serve as
receptors for both BAFF and APRIL, whereas the BAFF-R can
only bind BAFF (Figure 1).
BAFF and APRIL are produced by immune cells, including
macrophages, neutrophils, dendritic cells, B cells, activated
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TABLE 1 | The preferred reporting of systematic reviews and meta-analysis (PRISMA) checklist.
Section/topic # Checklist item Reported on
page #
TITLE




2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of
key findings; systematic review registration number.
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 2
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons,





5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration
information including registration number.
4
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language,




7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional
studies) in the search and date last searched.
4
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 4





10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for
obtaining and confirming data from investigators.
4
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.
5
Risk of bias in
individual
studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at




13 State the principal summary measures (e.g., risk ratio, difference in means). NA
Synthesis of
results
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g.,













Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each













20 For all outcomes considered (benefits or harms) present for each study: (a) simple summary data for each intervention




21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. NA
Risk of bias
across studies
22 Present results of any assessment of risk of bias across studies (see Item 15). NA
Additional
analysis




24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key
groups (e.g., healthcare providers, users, and policy makers).
9
(Continued)
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TABLE 1 | Continued
Section/topic # Checklist item Reported on
page #
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified
research, reporting bias).
9
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 9
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the
systematic review.
9
T cells, and interleukin-2-activated natural killer cells (only
BAFF), as well as by stromal cells (6). Whereas, APRIL is
cleaved intracellularly to a secreted soluble molecule, BAFF is
produced as a cell membrane-bound surface protein that can be
further processed by the action of the protease furin to soluble
BAFF. Both cytokines need to form homotrimers (more seldom,
heterotrimers consisting of BAFF and APRIL can be found in
certain pathological conditions, such as RA) to bind and activate
their receptors. Upon engagement, their receptors signal and
fulfill several functions in B cells and plasma cells. The BAFF-R
contributes to survival and maturation of transitional and naïve
B cells. TACI is crucial for T cell-independent B cell responses
to certain antigens, regulation of the B cell compartment, and
immunoglobulin (Ig) class switching (also called class-switch
recombination). BCMA mediates the homeostatic survival of
plasma cells. Thus, treatment with atacicept affects immature
and mature B cells and plasma cells by inhibiting their survival,
while sparing B cell progenitors and memory B cells. Levels of
serum IgG, IgM, and IgA and numbers of mature and total
circulating B cells are reduced by atacicept. Hence, interaction
of BAFF and APRIL with their receptors contribute to diseases
where (autoreactive) B cells, (auto-) antibodies or both play a
pathogenic role (8).
METHODS
Study Design and Protocol Registration
The PRISMA checklist guided the reporting of this systematic
review (Table 1) (9). A study protocol was designed in advance
defining our inclusion criteria and search strategy. It was
registered with PROSPERO number CRD42019110328.
Search Strategy
We searched the PubMed database as well as the reference list
of included studies for suitable clinical trials. The search was
conducted between 4 October 2016 and 26 July 2018. Our full
search strategy and research terms were defined in advance
(Table 2). We also used filters for randomized controlled trials
(RCTs). If publications were not available via open access or
through institutional access, study authors were contacted.
Eligibility Criteria
We included RCTs, their extension trials and their substudies
with predefined endpoints investigating the use of atacicept in
particular immunologic diseases mentioned above. If RCTs were
not available, we included non-randomized clinical studies with
TABLE 2 | Search terms.
Terms Results
1. Atacicept
2. Atacicept AND lupus




4. Atacicept AND multiple sclerosis
5. Atacicept AND multiple sclerosis; Filters: Randomized
Controlled Trial
6. Atacicept AND optic neuritis; Filters: Randomized Controlled
Trial





8. Atacicept AND rheumatoid arthritis




10. Atacicept and sjögrens syndrome 5
11. Atacicept and psoriasis
12. Atacicept and psoriatic arthritis
1
1
at least five patients per intervention group and case series
including at least three patients when the study design of case
series was prospective or unknown, whereas studies stating they
were retrospective were excluded. The minimum number of
patients was set to show a relevant treatment effect and to
minimize the risk of reporting bias. We also excluded post hoc-
analyses, meta-analyses, reviews, studies made from registries
and studies carried out on animal models or where the primary
endpoint was non-clinical. Studies had to be available in English
or German.
Study Selection, Data Collection Process
and Analysis
Two authors (CK and OB) developed and tested a data extraction
sheet, whereupon three authors independently (CK, US, and
BW) searched PubMed according to the predefined search
terms, checked titles and abstracts, carried out a full-text review
of the selected studies, and extracted the relevant data. Any
disagreements about study inclusion were resolved by consensus.
Risk of Bias Assessment
CK used a modified version of the Downs and Black tool
(see Table S1) to assess the retrieved studies for bias (10). The
studies were scored out of a maximum of 28 points for the
following categories: (i) reporting, (ii) external validity, (iii)
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internal validity, and (iv) power, and the scores were summed and
ranked high, medium and low quality. Any discrepancies were
resolved by consensus.We did not assess for risk of bias across the
studies since we supposed publication bias would be high when
restricting our search to PubMed and reference lists.
Principal Summary Measures and
Synthesis of Results
The aim of this systematic review is to provide a structured and
complete overview of the current available studies assessing the
efficacy and safety of atacicept as well as its influence on quality
of life when used in immune-mediated diseases. Since we wanted
to give an overview including also rare diseases we did not specify
in more detail these endpoints in order not to exclude potentially
important studies.
RESULTS
Study Selection and Characteristics
The search of PubMed for “atacicept” revealed a total of 118
citations. 50 articles were screened for eligibility according to
abstract and title. 34 were excluded using filters in the PubMed
FIGURE 2 | PRISMA diagram of the literature search.
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search. Review of the full-text of the remaining 16 articles
led to further exclusion of six trials. Finally, 10 studies were
incorporated in our review (see Figure 2). Study characteristics
are available in Table S2.
Synthesized Findings
Multiple Sclerosis
One double-blind, phase II RCT (ATAMS) investigating the use
of atacicept in 255 patients suffering frommultiple sclerosis (MS)
was retrieved (11). The main inclusion criteria for the ATAMS
trial was diagnosis of relapsing-remitting MS defined by the 2005
McDonald criteria. Patients suffering from primary or secondary
progressive MS were excluded. Study duration was 36 weeks with
an initially planned five year open-label extension part (named
ATAMS EXT).
Subcutaneous injections of atacicept were given twice weekly
during the first four weeks followed by weekly injections during
the following 32 weeks. Single doses ranged from 25 to 150mg.
The control group received a matching placebo.
Initially the primary endpoint in the ATAMS trial was a
change in the mean number of gadolinium-enhancing lesions
on T1-weighted MRI per patient scan between weeks 12 and 36.
This was later amended to between week 0 and 36. The primary
endpoint assessed in the ATAMS EXT trial was the number of
patients with treatment-emergent adverse events (AEs) or serious
adverse events (SAEs).
While the study was being conducted, an independent data
and safety monitoring board noted an increased annualized
relapse rate (significant in patients receiving 25 and 150mg
atacicept as compared to placebo). Thus, the ATAMS trial was
prematurely terminated. Only 67 patients in the atacicept group
and 23 patients in the placebo group completed the ATAMS
study. Remarkably, in the group receiving 75mg atacicept a
significant increase in T1-weighted MRI lesions was observed.
An open-label extension trial termed ATAMS EXT had been
initially planned as a five-year safety follow-up. However, none
of the patients entered the planned ATAMS EXT because of the
premature termination of the ATAMS trial.
131 out of 192 (68.2%) patients treated with atacicept had
at least one AE, compared to 46 out of 63 (73%) placebo-
treated patients. SAEs occurred in seven out of 192 (4%) patients
treated with atacicept and in one out of 63 (2%) placebo-treated
patients. One death due to myocardial infarction occurred in a
placebo-treated patient.
Change in health-related quality of life was not reported.
Discussion
The only available RCT investigating the use of atacicept in
patients with MS was terminated early due to an increased
annualized relapse rate and an increase in T1-weighted MRI
lesions. Thus, based on this evidence treatment with atacicept
does not seem to be effective.
Optic Neuritis
In a phase II randomized, double-blind controlled trial, 34
patients with an unilateral symptomatic optic neuritis (clinically
isolated syndrome) received either 150mg atacicept twice weekly
for four weeks followed by weekly injections or matching
placebo (12). Main exclusion criteria were a diagnosis of MS or
Devic’s disease.
The study was planned to last 36 weeks with a safety follow-
up of 12 weeks. Since the above-mentioned ATAMS study was
terminated early due to increased disease activity in MS patients,
the study sponsor stopped the ATON trial prematurely and added
a 60-week safety follow-up.
The primary endpoint of the study was the change in retinal
nerve fiber layer (RNFL) thickness from baseline to week 36.
The reduction in RNFL thickness was smaller in atacicept-
treated patients than in placebo-treated patients (p= 0.070) (12).
However, the proportion of patients who converted to clinically
definite MS was higher in the atacicept-treated patients.
The incidence of AEs and SAEs was comparable between
the two treatment groups. Patients receiving atacicept had more
injection site reactions.
Discussion
ATON is the only available trial in patients with optic neuritis
and showed an increased conversion to clinically definite MS.
Consequently, treatment with atacicept does not seem to be
promising in patients suffering from this disease.
Rheumatoid Arthritis
We identified four RCTs investigating the use of subcutaneous
atacicept versus placebo in rheumatoid arthritis (RA) (13–16).
All but one trial (14) included a 25-week double-blind period
with a follow-up of at least 13 weeks (13, 15, 16). In total, 665
adult patients with a diagnosis of RA according to the American
College of Rheumatology (ACR) criteria were randomized to
either atacicept or a control group. Minimum disease duration
ranged from six months (14, 15) to one year (13, 16). All
patients had active disease, which was mostly defined by the
number of tender and swollen joints as well as elevated C-reactive
protein (CRP) and erythrocyte sedimentation rate (ESR) levels
(13–15), except for one trial using the disease activity score
28 (DAS28) (16). Only the AUGUST I and III trials reported
concomitant corticosteroids, non-steroidal anti-inflammatory
drugs (NSAIDs) and methotrexate given at stable doses (13). The
other trials reported insufficiently about concomitant treatments.
The phase Ib trial from Tak et al. (14) was the first to
be published investigating the safety and tolerability of single
and repeated doses of subcutaneous atacicept, ranging from 70
to 630mg. The control group received placebo. Patients were
followed up for three months after the last administration. 24
out of 55 (44%) atacicept-treated patients and eight out of 18
(44%) placebo-treated patients had at least one AE. They reported
one SAE (pneumothorax) and one death (lung cancer), both in
patients that had received atacicept.
In the AUGUST I trial, which was a phase II study, patients
received either atacicept at doses of 25, 75, or 150mg twice weekly
for four weeks and then weekly for 21 weeks or a matching
placebo (13). The primary endpoint, ACR20 response at 26
weeks, was comparable between patients receiving atacicept and
placebo (p = 0.410). The same was true for the ACR50 and
ACR70 response rates. 71% of atacicept-treated patients versus
66% of placebo-treated patients experienced at least one AE
(13). 22 patients had at least one SAE, and two deaths occurred
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in the atacicept group, with one death considered unrelated
to the study. In patients receiving placebo, three subjects had
at least one SAE and no deaths were observed. To sum up,
atacicept led to increased AEs and SAEs, resulting in the trial
being discontinued.
The AUGUST II trial, the second phase II study, had three
active treatment arms, one receiving 150mg atacicept twice
weekly for four weeks and then weekly thereafter, one receiving
150mg atacicept weekly and a third one receiving open-label
40mg adalimumab every other week (15). The control group
received placebo. The primary endpoint was the same as in the
AUGUST I trial and was not met. However, patients receiving
open-label adalimumab achieved significantly more often an
ACR20 response than patients in the placebo group (p = 0.001).
Surprisingly, atacicept as well as adalimumab led to significantly
higher ACR50 response rates as compared to placebo (p < 0.05).
This effect was lost when assessing the ACR70 response rates,
where only adalimumab led to significantly better results than
placebo. The frequency of AEs was higher in atacicept treated
patients when compared to placebo. The occurrence of SAEs was
comparable between the groups.
In the AUGUST III trial, the third phase II study published,
atacicept was used as a maintenance therapy after induction
treatment with two 1,000mg infusions of rituximab (16). Safety
and tolerability were the primary endpoint of the study. 17 out
of 18 (94.4%) atacicept-treated patients and nine out of nine
(100%) placebo-treated patients experienced at least one AE,
and two SAEs were observed in each treatment group. However,
AEs leading to discontinuation were seen more often in the
atacicept group.
Discussion
The use of atacicept in patients suffering from RA was tested in
four different RCTs with rather disappointing results. Only one
trial found a significant effect of atacicept when looking at the
ACR50 response rate after 26 weeks.
Systemic Lupus Erythematosus
We identified four trials investigating atacicept in systemic
lupus erythematosus (SLE). All studies were double-blind
RCTs (5, 17–19). The study duration ranged from six to
76 weeks. The longest double-blind period was 52 weeks
(17). Two of the trials were terminated early due to safety
concerns (5, 17). In total, 797 patients were included in the
four trials.
A phase Ib study investigated the safety and tolerability of
atacicept given intravenously at different doses ranging from 3
mg/kg once to 2 × 9 mg/kg over three weeks in comparison
to placebo (18). 20 patients received atacicept and four placebo.
The authors reported nine patients with at least one AE in the
atacicept groups versus one patient with three AEs in the placebo
group. Only one SAE occurred in a patient treated with 2 × 9
mg/kg atacicept over three weeks (abscess of the ear in a patient
with a history of an ear cyst).
A phase II/III study by Ginzler et al. (17) planned to analyze
the percentage of patients suffering from active lupus nephritis
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to atacicept 150mg given twice weekly for four weeks and
weekly thereafter or matching placebo. Concomitant treatment
consisted of corticosteroids and mycophenolate mofetil. The
study was terminated early after enrollment of only six
patients due to safety concerns. Three of the four patients
receiving atacicept developed IgG levels below the protocol-
defined discontinuation level and in consequence suffered
infectious side effects (Haemophilus influenzae pneumonia with
empyema and septicemia, Legionella pneumophila pneumonia
and Bacillus bacteriemia).
A phase II/III trial by Isenberg et al. (5) studied the proportion
of patients with at least one flare of British Isles Lupus
Assessment Group (BILAG) A or B. Secondary endpoint was
time to first flare. Patients were randomized to receive 75mg
atacicept, 150mg atacicept or placebo. The 150mg atacicept
arm was terminated early due to two deaths in this group
(alveolar hemorrhage secondary to possible leptospirosis and
pneumococcal pneumonia with alveolar hemorrhage). Unlike the
Ginzler et al. study, the patients of the Isenberg et al. trial did not
develop hypogammaglobulinaemia. A post-hoc analysis of flare
rate and time to first flare in the 150mg atacicept group, showed
significant improvement when compared to placebo (p = 0.027
and p = 0.009, respectively). In contrast, the reported results for
the 75mg atacicept did not show any difference concerning the
primary and secondary endpoints in comparison to placebo. The
occurrence of AEs and SAEs was comparable between atacicept
and placebo.
In the ADDRESS II trial, a phase IIb placebo-controlled study,
atacicept was given weekly at a dose of either 75 or 150mg
(19). The proportion of patients with a SLE Responder Index
4 at 24 weeks was assessed as primary endpoint. Significantly
more patients in the 75mg atacicept, but not in the 150mg
atacicept group, reached the primary endpoint (p = 0.045).
AEs were reported slightly more frequently in patients receiving
atacicept, whereas a higher percentage of SAEs were noted in the
placebo group. No difference was reported in the patient global
assessment between patients treated with placebo versus those
treated with atacicept.
Discussion
Two of the four available trials were terminated early due to
safety concerns. To date, it remains unclear if the increased rate
of infections, which led to the discontinuation of the trials, was
caused by atacicept or by the concomitant treatment. However,
available information about efficacy is contradictory and further
studies are needed to draw a conclusion.
Risk of Bias Assessment
We assessed the quality and risk of bias of included studies using
a modified Downs and Black checklist (Table 3).
DISCUSSION
The trials conducted in patients with MS and optic
neuritis were both terminated early due to increased
disease activity. Patients with MS treated with atacicept
developed a higher annualized relapse rate and more
TABLE 4 | Adverse events.
Organ systems affected Adverse event(s) References
Systemic a) Immediate-type adverse reactions Infusion reactions (11–16, 18, 19)











Cardiovascular Palpitations, hypertension, hypotension, leucoytoclastic vasculitis, atrial fibrillation, ventricular
fibrillation, cardiorespiratory arrest
(5, 11, 13, 15–17)
Gastrointestinal and hepatic Nausea, gastritis, diarrhea (11–13, 16, 19)
Hematologic events Anemia, leukopenia, hypogammaglobulinemia (13, 14, 17–19)
Musculoskeletal Back pain, arthralgia, rheumatoid nodule, RA exacerbation, osteoarthritis, pelvic fracture (11–16, 19)
Nervous system (including
eyes)
fatigue, headache, conjunctivitis, hordeolum, visual impairment, acute psychosis, anxiety,
depressive feelings, transient ischemic attack, increased frequency of MS relapses,
progression to clinically definite MS, transverse myelitis, demyelination
(5, 11–16, 18, 19)
Renal Chronic pyelonephrits (14)
Upper and lower airways Nasopharyngitis, rhinitis, sinusitis, obstructive airway disorder, pneumonia, pyopneumothorax,
pneumothorax, dyspnea, laryngeal edema, pulmonary hypertension, alveolar hemorrhage
(5, 11–19)
Urogenital Spontaneous abortion (15)
Skin Erythema, pruritus, rash, itching, swelling, urticaria (11–16, 18, 19)
List of adverse events per organ system.
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new T1-weighted MRI lesions than patients receiving
placebo. Similar results were seen in patients with
optic neuritis. Atacicept led to a higher conversion rate
to clinically definite MS than placebo. Thus, further
investigation of atacicept in these two diseases does not
seem promising.
Of the four available trials conducted in RA patients only
the AUGUST II trial showed a significant treatment effect of
atacicept in comparison to placebo. The other three trials did not
show any significant results when analyzing the ACR response
rates. However, the frequency of AEs and SAEs was comparable
between atacicept and placebo.
Concerning SLE, it is noteworthy that belimumab, a human
monoclonal antibody targeting BAFF, has shown efficacy in a
subset of SLE patients (20). Thus, the expectation was that
atacicept, which interferes with receptor binding of both BAFF
and APRIL, would result in a similar, if not better, efficacy in
autoantibody-positive SLE patients. The trials assessing atacicept
in SLE conducted so far have been unable to show such outcome.
Accordingly, information on disease activity was only available
from two of the four available trials. The study of Isenberg
et al. failed to show a significant improvement after atacicept
treatment (5). In the ADDRESS II trial only patients receiving
75mg atacicept weekly showed a significantly better response
concerning the SLE Responder Index 4 (19). Remarkably, two
out of four studies were terminated early due to safety concerns
(5, 17). However, the latest trial published in 2018 did not show
a significant difference concerning safety events (19). Thus, it
remains unclear whether atacicept caused the observed safety
events or if it was the concomitant treatment. Further studies are
needed to answer this question.
Table 4 gives an overview of the current safety data.
Limitations
This is the first systematic review on the safety and efficacy of
atacicept in a number of immune-mediated diseases. We have
used standardized systematic overview techniques, which have
helped to minimize the risk of bias. Furthermore, we assessed
the quality and bias of each study using a modified version of the
Downs and Black checklist.
Nonetheless, our systematic review has certain limitations.
Firstly, we included studies with different outcome measures,
inclusion criteria, concomitant treatment, and study duration,
making a direct comparison difficult. Furthermore, although we
did not assess for risk of bias across the studies, we aimed to
minimize the risk by double-checking the presented data as well
as the inclusion of trials.
Conclusions
To sum up, atacicept failed to show a superior effect on
disease activity in comparison to placebo in patients suffering
from MS, optic neuritis, RA or SLE. In consequence the
treatment is neither approved by the EMA nor the FDA.
ClinicalTrials.gov currently lists one ongoing RCT investigating
the safety and efficacy of atacicept in patients with IgA
nephropathy (21). The primary outcome measures of this study
are the proportion of study subjects with AEs and SAEs as well
as the percent change from baseline in proteinuria at week 48,
whereas the secondary outcome measure consist in different
biomarkers, including e.g., change from baseline levels in serum
immunoglobulin classes, complement C3 and C4 levels, and
immune cell subsets.
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